Deleting a long noncoding RNA drives premature aging in mice.
Aging is a complex process that affects most living organisms. Over a century of research has revealed that many different intrinsic and extrinsic factors contribute to our bodies growing old, but we are still a long way from a full understanding of all the mechanisms at play. Recent research has implicated molecules that do not code for proteins in this process, such as long noncoding RNAs. For instance, many of these so-called 'lncRNAs' are expressed differently in patients with age-related disorders, such as various forms of neurodegenerative disease and cancer (Rinn and Chang, 2012).
Now, in eLife, Joshua Mendell of the University of Texas Southwestern Medical Center (UTSW) and colleagues – including Florian Kopp as first author – report that losing the long noncoding RNA Norad accelerates aging in mice (Kopp et al., 2019). Previous studies have shown that Norad is highly conserved in mammals, and that it is abundant in most human cells (Lee et al., 2016; Tichon et al., 2016). The production of Norad increases in response to DNA damage and it helps preserve the genetic information as cells divide. Norad is mainly found in the cytoplasm, where it can bind two PUMILIO proteins (PUM1 and PUM2) that regulate a variety of targets in the cell, including some involved in cell growth and division (Figure 1). Yet, it was unknown what deleting Norad would entail at the level of an organism.
To investigate this question, Kopp et al. – who are based at UTSW, the Nationwide Children's Hospital and Ohio State University – engineered mice that lacked Norad. As the mutant animals grew, they displayed signs of premature aging: their fur thinned down and grayed faster; their spine showed the abnormal curvature associated with old age; their fat reserves dwindled more quickly; and they died earlier. Mice lacking Norad also exhibited several cellular hallmarks of aging (López-Otín et al., 2013). Many of their cells had the wrong number of chromosomes (as previously seen in Norad-deficient human cells), as well as mitochondria that were showing defects. This was associated with the repression of PUMILIO targets that keep mitochondria working properly. Strikingly, mice engineered to over-produce PUM2 had similar characteristics, clearly indicating that the hyperactivity of PUMILIO drives the symptoms associated with a lack of Norad (Figure 1).
On the flipside, a recent study in humans showed that halving the dose of PUM1 leads to developmental delay and seizures (Gennarino et al., 2018), and reducing the amount of PUM1, PUM2, or both results in smaller body size (Lin et al., 2019). These results suggest that mammals must maintain the activity of PUMILIO proteins within a narrow range in order to remain healthy. In fact, the levels of PUM2 proteins in bulk tissues are indistinguishable between control mice and animals that overexpress Pum2. Furthermore, in both Norad-deficient and Pum2-overexpressing mice, most PUMILIO targets are only affected very mildly, yet the animals exhibit striking phenotypes. Kopp et al. argue that repressing many PUMILIO targets at the same time, even weakly, may trigger the physiological damages observed in these rodents.
Still, it may also be possible that when the Norad-PUMILIO axis is disrupted, certain cells or tissues are more likely to stop working properly, which in turn creates a snowball effect for the whole organism. For instance, the expression of Norad is highest in the human brain, but it decreases with age in a region that acts as a reservoir to regenerate brain cells (Barry et al., 2015). In simpler organisms, such as the worm C. elegans, the nervous system acts on other tissues to coordinate pathways that keep proteins in their normal conformation, but these mechanisms become defective with age (van Oosten-Hawle and Morimoto, 2014). It remains unclear whether the nervous system performs such roles in mammals; yet, these results raise the possibility that interactions between Norad and PUMILIO are needed in specific tissues to ward off the effects of age.
Norad is PUMILIO’s preferred target, and has several binding sites that are recognized by these proteins. This suggests that this lncRNA can bind a large number of PUMILIO proteins at any given moment, but it is still unclear whether Norad tempers the activity of PUM1 and PUM2 simply by competing with other targets of PUMILIO, or if another mechanism is at play (Goldstrohm et al., 2018; Tichon et al., 2018).
Curiously, Norad is only found in mammals, whereas the PUMILIO proteins are found in all eukaryotes; it is therefore possible that RNAs with different sequences also buffer the activity of PUMILIO in other species. It remains to be seen how and why mammalian cells rely on Norad to tame the activity of these proteins, as opposed to other types of regulatory mechanisms. Ultimately, the work by Kopp et al. sets the ground for further enquiries into the role of noncoding RNAs and RNA-binding proteins in aging, which could potentially yield new therapeutic approaches for diseases brought by old age.
Post-transcriptional regulatory functions of mammalian Pumilio proteinsTrends in Genetics 34:972–990.https://doi.org/10.1016/j.tig.2018.09.006
Genome regulation by long noncoding RNAsAnnual Review of Biochemistry 81:145–166.https://doi.org/10.1146/annurev-biochem-051410-092902
Downloads (link to download the article as PDF)
Download citations (links to download the citations from this article in formats compatible with various reference manager tools)
Open citations (links to open the citations from this article in various online reference manager services)
APOBEC3B (A3B)-catalyzed DNA cytosine deamination contributes to the overall mutational landscape in breast cancer. Molecular mechanisms responsible for A3B upregulation in cancer are poorly understood. Here, we show that a single E2F cis-element mediates repression in normal cells and that expression is activated by its mutational disruption in a reporter construct or the endogenous A3B gene. The same E2F site is required for A3B induction by polyomavirus T antigen indicating a shared molecular mechanism. Proteomic and biochemical experiments demonstrate binding of wildtype but not mutant E2F promoters by repressive PRC1.6/E2F6 and DREAM/E2F4 complexes. Knockdown and overexpression studies confirm involvement of these repressive complexes in regulating A3B expression. Altogether, these studies demonstrate that A3B expression is suppressed in normal cells by repressive E2F complexes and that viral or mutational disruption of this regulatory network triggers overexpression in breast cancer and provides fuel for tumor evolution.
Lysine 27-to-methionine (K27M) mutations in the H3.1 or H3.3 histone genes are characteristic of pediatric diffuse midline gliomas (DMGs). These oncohistone mutations dominantly inhibit histone H3K27 trimethylation and silencing, but it is unknown how oncohistone type affects gliomagenesis. We show that the genomic distributions of H3.1 and H3.3 oncohistones in human patient-derived DMG cells are consistent with the DNAreplication-coupled deposition of histone H3.1 and the predominant replication-independent deposition of histone H3.3. Although H3K27 trimethylation is reduced for both oncohistone types, H3.3K27M-bearing cells retain some domains, and only H3.1K27M-bearing cells lack H3K27 trimethylation. Neither oncohistone interferes with PRC2 binding. Using Drosophila as a model, we demonstrate that inhibition of H3K27 trimethylation occurs only when H3K27M oncohistones are deposited into chromatin and only when expressed in cycling cells. We propose that oncohistones inhibit the H3K27 methyltransferase as chromatin patterns are being duplicated in proliferating cells, predisposing them to tumorigenesis.